Conatus Pharmaceuticals Inc. (CNAT)

5.37
0.01 0.19
NASDAQ : Health Technology
Prev Close 5.38
Open 5.40
Day Low/High 5.34 / 5.50
52 Wk Low/High 3.88 / 9.40
Volume 164.72K
Avg Volume 373.80K
Exchange NASDAQ
Shares Outstanding 30.00M
Market Cap 153.63M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Buy Conatus Pharmaceuticals At $2.50, Earn 9.4% Annualized Using Options

Investors eyeing a purchase of Conatus Pharmaceuticals Inc stock, but cautious about paying the going market price of $4.07/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2018 put at the $2.50 strike, which has a bid at the time of this writing of 10 cents.

Short Interest Decreases By 30.6% For CNAT

Short Interest Decreases By 30.6% For CNAT

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 642,982 share decrease in total short interest for Conatus Pharmaceuticals Inc , to 1,461,190, a decrease of 30.56% since 10/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Oversold Conditions For Conatus Pharmaceuticals (CNAT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Conatus Pharmaceuticals Announces Poster Presentation At AASLD Annual Meeting

Conatus Pharmaceuticals Announces Poster Presentation At AASLD Annual Meeting

Pan-caspase Inhibitor IDN-7314 Reduces Liver Injury Due to Intestinal Bacteria Imbalance Resulting from Restricted Bile Flow in Mouse Model of PSC

Conatus Pharmaceuticals Announces Poster Presentation At International Liver Cell Conference

Emricasan Improves and Sustains Key Functions in Cirrhotic Liver Cells

Fewer Oars Make Market Tough Row to Hoe

Fewer Oars Make Market Tough Row to Hoe

Investors should be more cautious heading into the summer.

First Week of CNAT June 16th Options Trading

Investors in Conatus Pharmaceuticals Inc saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CNAT options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

The Only Choice: Find Something to Buy

The Only Choice: Find Something to Buy

If you can't beat them, then join them.